FUNDED BY THE STUART SCOTT MEMORIAL CANCER RESEARCH FUND WITH SUPPORT FROM BRISTOL MYERS SQUIBB
Ovarian cancer is a deadly disease. A goal of ovarian cancer treatment is to find drugs that allow patients to live longer. The methods that predict whether these drugs work ignore proteins. There is no information about how proteins affect survival. Also, it is not known how proteins contribute to harmful side effects. In this project, we will identify the proteins that are involved in responding to a group of drugs named PARP inhibitors. These drugs are used to treat patients with the most deadly form of ovarian cancer. It is critical to identify the proteins associated with good PARP inhibitor response. This will help us to understand how PARP inhibitors have anti-cancer activity. As a result, it will be easier to identify the ovarian cancer patients who will respond to PARP inhibitor treatment. This research project supports the goal of the V Foundation, and it will help to accelerate victory over ovarian cancer.